Viridian Therapeutics, Inc.\DE (VRDN) Capital Expenditures (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Capital Expenditures of $23000.0 for Q1 2026, down 73.26% year-over-year from $86000.0 in Q1 2025, and down 90.42% quarter-over-quarter from $240000.0 in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Capital Expenditures (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Capital Expenditures history runs 13 years deep, the most recent figure standing at $23000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 73.26% year-over-year to $23000.0; the TTM figure through Mar 2026 stood at $432000.0 (down 27.64% YoY), while the FY2025 annual figure was $495000.0, down 3.13% from the prior year.
- Capital Expenditures for Q1 2026 stood at $23000.0, down from $240000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $566000.0 in Q3 2022, with the low at -$186000.0 in Q4 2022.
- The 5-year median for Capital Expenditures is $114500.0 (2023), against an average of $144187.5.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures plunged 359.42% in 2022, then jumped 284.92% in 2023.
- Viridian Therapeutics, Inc.\DE's Capital Expenditures stood at -$186000.0 in 2022, then soared by 125.81% to $48000.0 in 2023, then jumped by 137.5% to $114000.0 in 2024, then soared by 110.53% to $240000.0 in 2025, then tumbled by 90.42% to $23000.0 in 2026.
- Business Quant data shows VRDN's Capital Expenditures at $23000.0 in Q1 2026, $240000.0 in Q4 2025, and $127000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 1.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.31 Mn |
| Jun 30, 2026 | 1.31 Mn |
| Mar 31, 2026 | 23,000.00 |
| Mar 31, 2026 | 23,000.00 |
| Dec 31, 2025 | 240,000.00 |
| Dec 31, 2025 | 240,000.00 |
| Sep 30, 2025 | 127,000.00 |
| Sep 30, 2025 | 127,000.00 |
| Jun 30, 2025 | 42,000.00 |
| Jun 30, 2025 | 42,000.00 |
| Mar 31, 2025 | 86,000.00 |
| Mar 31, 2025 | 86,000.00 |
| Dec 31, 2024 | 114,000.00 |
| Dec 31, 2024 | 114,000.00 |
| Sep 30, 2024 | 293,000.00 |
| Sep 30, 2024 | 293,000.00 |
| Jun 30, 2024 | 104,000.00 |
| Jun 30, 2024 | 104,000.00 |
| Dec 31, 2023 | 48,000.00 |
| Dec 31, 2023 | 48,000.00 |